Hospital Universitario Hermanos Trias y Pujol. Institut Catalá d'Oncología (ICO)
- Address
- Carretera Canyet 1a Planta, 08916 Badalona, Spain
Hematology and Immune-Related Oncology Research
At Hospital Universitario Hermanos Trias y Pujol and the Institut Catalá d'Oncología (ICO) in Badalona, clinical research in oncology focuses on hemic and lymphatic diseases as well as immune system diseases. The studies are centered on improving treatment options for blood cancers, especially acute myeloid leukemia, while also exploring broader cancer-related care.
- Evaluating new treatment approaches for acute myeloid leukemia to improve remission outcomes
- Comparing different ways to use established therapies in hematologic malignancies for better effectiveness and safety
- Supporting research in immune system diseases linked to oncology care and blood disorders
This research site is contributing to studies that aim to refine treatment strategies, strengthen response rates, and make care more effective for patients with complex blood-related cancers.
Acute Myeloid Leukemia Clinical Trials
A major part of the trial activity at this site is dedicated to acute myeloid leukemia, with studies designed to test whether modified treatment approaches can maintain strong results while potentially improving tolerability. These trials are focused on patients who are not candidates for intensive induction therapy and seek to optimize real-world treatment effectiveness.
- Testing a new way to combine and schedule therapies for acute myeloid leukemia
- Assessing whether shorter exposure to treatment can preserve remission outcomes
- Improving the balance between treatment effectiveness and safety in blood cancer care
The research reflects a strong interest in finding practical, patient-friendly options for leukemia management, with a clear emphasis on response quality and clinical benefit.
Blood Cancer and Oncology Treatment Innovation
The oncology program at this health care site includes trials aimed at advancing care for hemic and lymphatic diseases. The main goal is to evaluate whether updated treatment strategies can improve outcomes for people living with difficult-to-treat blood cancers, especially acute myeloid leukemia.
- Studying treatment effectiveness in blood cancer populations
- Exploring better-supported options for patients with limited treatment tolerance
- Contributing to evidence that may guide future cancer care
With multiple investigators involved, the site supports collaborative clinical research that aims to improve outcomes and inform more tailored approaches in oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 32 therapeutic areas and 15 of 637 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 584 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 119 by active trials.
- 1AstraZeneca AB7active
lock +118 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB23trials
lock +73 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Hermanos Trias y Pujol. Institut Catalá d'Oncología (ICO)
lock Showing 1 of 480 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week Randomized Double-Blind Trial Comparing CHF5993 (Beclometasone Dipropionate, Formoterol Fumarate, Glycopyrronium Bromide) to Fluticasone Propionate/Salmeterol in Adolescents with Uncontrolled Asthma | Chiesi Farmaceutici S.p.A. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 637 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 23 | Unknown | 2018-03-21 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.